# Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

> **NCT02611778** · PHASE3 · COMPLETED · sponsor: **Bioeq GmbH** · enrollment: 712 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **BIOLOGICAL:** ranibizumab

## Key facts

- **NCT ID:** NCT02611778
- **Lead sponsor:** Bioeq GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-19
- **Primary completion:** 2017-12
- **Final completion:** 2018-06-06
- **Target enrollment:** 712 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611778, "Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02611778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*